Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

MPN Congress 2022 and Myelofibrosis View overview page

Factoring in symptoms into managing MPNs
Ruben Mesa • 24 Nov 2022
Promising new MPN treatments
John Mascarenhas • 24 Nov 2022
Combining novel agents for treating myelofibrosis
Naveen Pemmaraju • 24 Nov 2022
Optimizing current JAK2 inhibitors in myelofibrosis
Srdan Verstovsek • 24 Nov 2022
A paradigm shift in the diagnosis and treatment of MPNs
Hans Hasselbalch • 24 Nov 2022
The MPN microenvironment
Angela Fleischman • 24 Nov 2022
Leveraging inflammatory cytokine signaling for therapeutic benefit in MPNs
Stephen Oh • 24 Nov 2022
Are megakaryocytes the root of MPN evils?
Joseph Scandura • 24 Nov 2022
Pursuing monoclonal antibodies for MPNs: targeting mutant calreticulin
Ann Mullally • 24 Nov 2022
1:46
The role of CALR mutations in the initiation and progression of MPNs
Ann Mullally • 31 Oct 2022
7:03
JAK2 V617F VAF as a diagnostic and prognostic marker for polycythemia vera and thrombosis risk
Alison Moliterno • 31 Oct 2022
2:21
The clinical significance of splenomegaly in polycythemia vera
Ghaith Abu-Zeinah • 3 Nov 2022
1:47
The central role of megakaryocytes in MPN pathophysiology
Joseph Scandura • 31 Oct 2022
3:23
The role of rusfertide in polycythemia vera
Richard Silver • 18 Oct 2022
6:19
Management of patients with PV who are intolerant to interferon and who develop post-polycythemic MF
Richard Silver • 18 Oct 2022
2:50
Looking forward to the 2022 MPN Congress
Richard Silver • 18 Oct 2022
The content of VJHemOnc is intended for healthcare professionals